Showing results (141-150 of 777) with videos related to

Sort By:
Pageof 78
Leukemia|April 3, 2020
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathwaysTeru Hideshima, Daisuke Ogiya, Jiye Liu, et al.
Blood Cancer Journal|December 10, 2023
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myelomaDebasmita Dutta, Jiye Liu, Kenneth Wen, et al.
Blood|November 9, 2002
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.
Cancer Cell|October 6, 2009
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic targetDharminder Chauhan, Ajita V Singh, Mohan Brahmandam, et al.
Blood|May 19, 2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisYu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, et al.
Blood|May 7, 2009
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaMariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, et al.
Expert Opinion on Emerging Drugs|March 16, 2007
Emerging drugs in multiple myelomaIrene M Ghobrial, Xavier Leleu, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|September 1, 2007
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsTeru Hideshima, Laurence Catley, Noopur Raje, et al.
Blood|January 14, 2017
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myelomaTeru Hideshima, Francesca Cottini, Yoshihisa Nozawa, et al.
Biochemical and Biophysical Research Communications|December 3, 2002
The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferationToru Yamaguchi, Mika Yamauchi, Toshitsugu Sugimoto, et al.
Pageof 78